• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[标准风险急性淋巴细胞白血病患儿高剂量甲氨蝶呤(3 g/m²)的清除率及耐受性评估]

[Assessment of elimination and tolerance of high dose of methotrexate (3 g/m2) in children with standard-risk acute lymphoblastic leukemia].

作者信息

Cwliklińska Magdalena, Balwierz Walentyna, Nowak Jacek, Stanuch Helena

机构信息

Klinika Onkologii i Hematologii Dzieciecej P-A Instytutu Pediatrii Collegium Medicum Uniwersytetu Jagiellońskiego w Krakowie.

出版信息

Przegl Lek. 2006;63(1):15-20.

PMID:16892893
Abstract

We assessed correlation between the elimination of methotrexate administered in dose 3 g/m2 during consolidation phase and the early complications in 129 children treated for acute lymphoblastic leukemia. Among 500 chemotherapy cycles included in the analysis the elimination of methotrexate was delayed in 66 (13.2%) cycles in 43 (33.3%) of patients. Influence of methotrexate on selected liver and renal function tests was analyzed. We made an attempt of early identification of patients with high risk for delayed methotrexate elimination and subsequent toxicities.

摘要

我们评估了129例接受急性淋巴细胞白血病治疗的儿童在巩固期给予3 g/m²剂量甲氨蝶呤后的清除情况与早期并发症之间的相关性。在纳入分析的500个化疗周期中,43例(33.3%)患者的66个周期(13.2%)中甲氨蝶呤清除延迟。分析了甲氨蝶呤对选定的肝功能和肾功能检查的影响。我们尝试早期识别甲氨蝶呤清除延迟及后续毒性高危患者。

相似文献

1
[Assessment of elimination and tolerance of high dose of methotrexate (3 g/m2) in children with standard-risk acute lymphoblastic leukemia].[标准风险急性淋巴细胞白血病患儿高剂量甲氨蝶呤(3 g/m²)的清除率及耐受性评估]
Przegl Lek. 2006;63(1):15-20.
2
[Study on elimination delay in high dose methotrexate therapy in childhood acute lymphoblastic leukemia].[儿童急性淋巴细胞白血病大剂量甲氨蝶呤治疗中清除延迟的研究]
Zhonghua Xue Ye Xue Za Zhi. 2005 Jan;26(1):15-8.
3
Comparison of long-term neurocognitive outcomes in young children with acute lymphoblastic leukemia treated with cranial radiation or high-dose or very high-dose intravenous methotrexate.接受头颅放疗或高剂量或极高剂量静脉注射甲氨蝶呤治疗的急性淋巴细胞白血病幼儿的长期神经认知结局比较。
J Clin Oncol. 2006 Aug 20;24(24):3858-64. doi: 10.1200/JCO.2006.05.9055.
4
Retrospective study on elimination delay of methotrexate in high-dose therapy of childhood acute lymphoblastic leukemia in China.中国儿童急性淋巴细胞白血病大剂量治疗中氨甲蝶呤清除延迟的回顾性研究
J Pediatr Hematol Oncol. 2007 Oct;29(10):688-93. doi: 10.1097/MPH.0b013e31814d6777.
5
High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.儿童急性淋巴细胞白血病的大剂量甲氨蝶呤治疗:血清甲氨蝶呤浓度与肌酐清除率之间无相关性。
Pediatr Blood Cancer. 2004 Jul;43(1):17-22. doi: 10.1002/pbc.20032.
6
[Treatment results in children with the standard risk acute lymphoblastic leukemia treated with high dose of methotrexate (5.0 g/m2). 11 years of the Polish Pediatric Leukemia/Lymphoma Study Group experience].[采用大剂量甲氨蝶呤(5.0 g/m²)治疗儿童标准风险急性淋巴细胞白血病的结果。波兰儿童白血病/淋巴瘤研究组11年的经验]
Przegl Lek. 2006;63(1):7-10.
7
High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL).大剂量甲氨蝶呤:关于264名瑞典急性淋巴细胞白血病(ALL)儿童的1164个疗程中甲氨蝶呤清除时间与肾功能及血清甲氨蝶呤水平的关系
Cancer Chemother Pharmacol. 2003 Apr;51(4):311-20. doi: 10.1007/s00280-002-0552-1. Epub 2003 Mar 28.
8
[High methotrexate doses in the treatment program for acute lymphoblastic leukemia and lymphosarcoma in children].[高剂量甲氨蝶呤用于儿童急性淋巴细胞白血病和淋巴肉瘤的治疗方案]
Vopr Onkol. 1990;36(10):1196-200.
9
Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.儿童急性淋巴细胞白血病大剂量甲氨蝶呤治疗后的药代动力学和毒性比较。
Anticancer Drugs. 2013 Feb;24(2):189-97. doi: 10.1097/CAD.0b013e32835b8662.
10
[Pharmacokinetic analysis of high-dose methotrexate treatments in children with hematologic malignancies].[大剂量甲氨蝶呤治疗血液系统恶性肿瘤患儿的药代动力学分析]
Orv Hetil. 2011 Oct 2;152(40):1609-17. doi: 10.1556/OH.2011.29143.